MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/idr.s579272

Медицинская библиотека · Infection and drug resistance · 2026

The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody.

Muflihah Heni, Yulianto Fajar Awalia, Maharani Winni, Hanipan Anis Rapiq

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Vaccination or infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce specific antibodies. The level of anti-spike receptor-binding (RBD) antibody may last long and interact with the immune response to tuberculosis (TB). We aimed to investigate the impact of the anti-RBD antibody level at baseline on the outcome of the intensive phase of TB treatment.

PATIENTS AND

METHODS

This cohort study recruited newly diagnosed TB patients from September 2022 to May 2023. Observation was conducted at baseline and after two months of TB treatment. Interviews and physical examinations were performed for patients with a history of Coronavirus Disease 2019 (COVID-19) vaccination or infection and anthropometric data, respectively. Peripheral blood was collected for baseline assessment of anti-RBD antibodies, an interferon gamma release assay (IGRA), and complete blood count. The clinical outcomes of TB treatment include sputum conversion, hematology parameters and body mass index (BMI).

RESULTS

Among the 63 participants, the majority were vaccinated for COVID-19 (73,02%), underweight (58.73%), and IGRA positive (79,03%), increased median ESR (71.5 (IQR 18-111) mm/hour), and slightly low median lymphocyte proportion (19.5 (IQR 7-33) %) at baseline. The median titer of anti-RBD antibodies at baseline was 1,584.2 (IQR 95.6-34,379.3) AU/mL/. At two months of TB treatment, all the returned participants had sputum conversion and improved BMI and normal hematology parameters. The anti-RBD antibody level was associated with the baseline BMI (β =0.00019, 95% CI: 0.0001-0.0003, p=0.00) and post treatment lymphocyte count (β=0.0003 (95% CI: 0.0001-0.001, p=0.02).

CONCLUSION

Our study revealed that susceptible TB patients had favorable outcomes after 2 months of TB treatment when baseline anti-RBD antibody was high at baseline. We suggest that larger studies are needed to confirm the relationship.

Для цитирования: Muflihah Heni, Yulianto Fajar Awalia, Maharani Winni, Hanipan Anis Rapiq. The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody.. Infection and drug resistance. 2026. DOI: 10.2147/idr.s579272.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.